VC-backed Entasis Therapeutics debuts IPO
Waltham, Massachusetts-based Entasis Therapeutics, a biopharmaceutical company focused on developing new antibacterial products, has raised about $75 million for its IPO after pricing its 5 million shares at $15 per share. The stock began trading September 26, 2018 on the NASDAQ under the ticker symbol "ETTX." Credit Suisse and BMO Capital Markets are the lead underwriters. Entasis' pre-IPO backers include Pivotal bioVenture Partners, Sofinnova Ventures and TPG Biotech.
26 September 2018•3 mins read
